Insmed Incorporated (INSM)
Automate Your Wheel Strategy on INSM
With Tiblio's Option Bot, you can configure your own wheel strategy including INSM - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol INSM
- Rev/Share 2.1068
- Book/Share 0.5483
- PB 192.2797
- Debt/Equity 11.5307
- CurrentRatio 5.8633
- ROIC -0.5609
- MktCap 20024634420.0
- FreeCF/Share -4.3639
- PFCF -25.3718
- PE -18.8167
- Debt/Assets 0.6342
- DivYield 0
- ROE -4.4698
- Rating D+
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | INSM | Jefferies | -- | Buy | -- | $105 | May 13, 2025 |
| Initiation | INSM | RBC Capital Mkts | -- | Outperform | -- | $100 | Feb. 25, 2025 |
News
Insmed Stock Jumps 29% on Encouraging PAH Study Results
Published: June 11, 2025 by: Zacks Investment Research
Sentiment: Positive
INSM eyes the next steps as TPIP hits all endpoints in the PAH study, setting the stage for late-stage trials and broader potential in lung disease.
Read More
Insmed shares surge on positive trial results for pulmonary arterial hypertension therapy
Published: June 10, 2025 by: Proactive Investors
Sentiment: Positive
Insmed Incorporated (NASDAQ:INSM) shares surged more than 27% after the company unveiled positive results from a Phase 2b of its once-daily pulmonary arterial hypertension (PAH) therapy, treprostinil palmitil inhalation powder (TPIP). The randomized, double-blind, placebo-controlled study met its primary endpoint as well as all secondary efficacy endpoints.
Read More
Insmed's Q1 Loss Wider Than Expected, Sales Match Estimates
Published: May 09, 2025 by: Zacks Investment Research
Sentiment: Neutral
INSM posts wider-than-expected loss in the first quarter. It reiterates the 2025 sales outlook for Arikayce in the range of $405-$425 million.
Read More
Insmed Incorporated (INSM) Q1 2025 Earnings Call Transcript
Published: May 08, 2025 by: Seeking Alpha
Sentiment: Neutral
Insmed Incorporated (NASDAQ:INSM ) Q1 2025 Earnings Conference Call May 8, 2025 8:00 AM ET Company Participants Bryan Dunn - Investor Relations Will Lewis - Chair and Chief Executive Officer Sara Bonstein - Chief Financial Officer Martina Flammer - Chief Medical Officer Conference Call Participants Andrea Newkirk - Goldman Sachs Jason Zemansky - Bank of America Nick Lenard - JPMorgan Joe Schwartz - Leerink Partners Ritu Baral - TD Cowen Jennifer Kim - Cantor Fitzgerald Liisa Bayko - Evercore Graig Suvannavejh - Mizuho Securities Leonid Timashev - RBC Nicole Germino - Truist Securities Maxwell Skor - Morgan Stanley Trung Huynh …
Read More
Insmed (INSM) Reports Q1 Loss, Tops Revenue Estimates
Published: May 08, 2025 by: Zacks Investment Research
Sentiment: Negative
Insmed (INSM) came out with a quarterly loss of $1.42 per share versus the Zacks Consensus Estimate of a loss of $1.36. This compares to loss of $1.06 per share a year ago.
Read More
Insmed Reports First-Quarter 2025 Financial Results and Provides Business Update
Published: May 08, 2025 by: PRNewsWire
Sentiment: Neutral
—ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $92.8 Million for the First Quarter of 2025, Reflecting 23% Growth Over the First Quarter of 2024— —NDA for Brensocatib in Patients with Bronchiectasis Remains on Track, with a PDUFA Target Action Date of August 12, 2025— —Phase 2b Study of TPIP in Patients with PAH Completed; Topline Data Expected in June 2025— —Enrollment Completed for Phase 2b BiRCh Study of Brensocatib in Patients with CRSsNP; Topline Data Anticipated By the End of 2025— —MAA Filings for Brensocatib in Patients with Bronchiectasis Accepted by EMA and MHRA— —Company Reiterates 2025 Global ARIKAYCE …
Read More
Earnings Preview: Insmed (INSM) Q1 Earnings Expected to Decline
Published: May 01, 2025 by: Zacks Investment Research
Sentiment: Negative
Insmed (INSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
Baron Health Care Fund Q1 2025 Top Contributors And Detractors
Published: April 29, 2025 by: Seeking Alpha
Sentiment: Positive
Boston Scientific's shares rose due to strong market growth, innovative products like pulsed field ablation, and disciplined cost management, driving double-digit EPS growth. Vertex Pharmaceuticals saw increased investor confidence in its cystic fibrosis franchise and evolving pipeline, including promising non-opioid pain treatments and kidney disease drugs. UnitedHealth Group's shares gained as 2024 headwinds subsided, Medicare Advantage rates improved, and higher-margin Optum segments grew, insulating it from tariff impacts.
Read More
Insmed: Poised For Transformation Beyond ARIKAYCE
Published: April 25, 2025 by: Seeking Alpha
Sentiment: Positive
Insmed's future hinges on the development and launch of its pipeline, particularly brensocatib, despite current financial losses due to strategic investments. Brensocatib shows promising Phase 3 results for non-cystic fibrosis bronchiectasis, with a potential FDA approval by August 2025, highlighting a significant market opportunity. Insmed's diversified pipeline, including TPIP and INS1201, reduces reliance on a single product and enhances long-term growth prospects.
Read More
Insmed to Present 11 Abstracts from Across Its Respiratory Portfolio at the American Thoracic Society 2025 International Conference
Published: March 25, 2025 by: PRNewsWire
Sentiment: Neutral
—New Analyses from the Phase 3 ASPEN Study Examining Efficacy and Safety of Brensocatib Across a Variety of Prespecified Subgroups— —Data from ASPEN Post-hoc Analysis Evaluating Changes in Lung Function in Bronchiectasis Patients Who Did or Did Not Experience Pulmonary Exacerbations in the Trial— — Data on Health Status Improvements Over Time Following Culture Conversion in Patients with Mycobacterium Avium Complex (MAC) Lung Disease— BRIDGEWATER, N.J. , March 25, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that …
Read More
Insmed Announces that FDA Does Not Currently Plan to Hold Advisory Committee Meeting to Discuss New Drug Application for Brensocatib in Patients with Bronchiectasis
Published: February 24, 2025 by: PRNewsWire
Sentiment: Neutral
—FDA Reaffirms Application is Under Priority Review with a PDUFA Target Action Date of August 12, 2025— BRIDGEWATER, N.J. , Feb. 24, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that the U.S. Food and Drug Administration (FDA) has informed the Company that it does not currently plan to hold an advisory committee meeting to discuss the New Drug Application (NDA) for brensocatib for patients with non-cystic fibrosis bronchiectasis.
Read More
Insmed Incorporated (INSM) Q4 2024 Earnings Call Transcript
Published: February 20, 2025 by: Seeking Alpha
Sentiment: Neutral
Insmed Incorporated (INSM) Q4 2024 Earnings Call Transcript
Read More
Insmed Reports Fourth-Quarter and Full-Year 2024 Financial Results and Provides Business Update
Published: February 20, 2025 by: PRNewsWire
Sentiment: Neutral
—ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $104.4 Million for Fourth-Quarter and $363.7 Million for Full-Year 2024, Reflecting 19% Annual Growth and Exceeding the Upper End of Full-Year 2024 Guidance Range— —Company Reiterates 2025 Global ARIKAYCE Revenue Guidance of $405 Million to $425 Million, Reflecting Double-Digit Growth Compared to 2024— —NDA for Brensocatib in Patients with Bronchiectasis Accepted by FDA and Granted Priority Review with a PDUFA Target Action Date of August 12, 2025— —Phase 2b Study of TPIP in Patients with PAH, Phase 2b BiRCh Study of Brensocatib in Patients with CRSsNP, and Phase 3 ENCORE Study of …
Read More
Insmed To Present at March 2025 Investor Conferences
Published: February 11, 2025 by: PRNewsWire
Sentiment: Neutral
BRIDGEWATER, N.J. , Feb. 11, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that management will present at the following investor conferences: 45th Annual TD Cowen Healthcare Conference in Boston, on Monday, March 3, 2025, at 9:10 a.m.
Read More
About Insmed Incorporated (INSM)
- IPO Date 2000-06-01
- Website https://www.insmed.com
- Industry Medical - Pharmaceuticals
- CEO Mr. William H. Lewis J.D., M.B.A.
- Employees 1271